TABLE 4.

Association Between Sex and OS on Multivariate Analysis

	Adjusted Median OS (95% CI), Months		HR (95% CI)a	P a
Subjects	Male	Female
All	10 (10–10)	11 (11–12)	0.93 (0.91–0.96)	<.001
Age group, y
18–44	10 (9–11)	14 (12–16)	0.75 (0.65–0.86)	<.001
45–54	11 (11–12)	13 (12–15)	0.86 (0.79–0.92)	<.001
55–64	12 (11–12)	14 (13–15)	0.86 (0.81–0.91)	<.001
65–74	10 (10–11)	11 (10–12)	0.97 (0.92–1.02)	.19
≥75	8 (7–8)	7 (7–8)	1.04 (0.99–1.10)	.15
P interaction		<.001
Race
White	10 (10–10)	11 (10–11)	0.93 (0.89–0.96)	<.001
African American	8 (7–8)	9 (9–10)	0.85 (0.78–0.92)	<.001
Asian	12 (12–13)	13 (12–14)	1.00 (0.94–1.06)	.87
Hispanic	10 (10–11)	11 (10–12)	0.99 (0.92–1.07)	.79
P interaction		.017
Stage
Single lesion	26 (25–27)	29 (27–31)	0.95 (0.90–1.01)	.086
Multiple tumors	13 (13–14)	14 (13–15)	0.96 (0.90–1.03)	.24
Vascular invasion	8 (8–9)	9 (9–10)	0.91 (0.87–0.95)	<.001
Metastatic disease	4 (3–4)	4 (3–4)	0.94 (0.88–1.00)	.055
P interaction		.036
Treatment
None or unknown	7 (6–7)	7 (7–7)	0.96 (0.93–0.99)	.017
Liver-directed therapy	27 (25–28)	27 (25–30)	0.99 (0.89–1.09)	.82
Surgical resection	44 (40–46)	48 (44–54)	0.87 (0.78–0.96)	.008
Liver transplantation	60b	60b	1.06 (0.86– 1.29)	.60
P interaction		.045

Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; OS, overall survival.

^aMen as the reference group (HR, 1).

^bEstimates were not reached.